- In patients with newly diagnosed stage III/IV Hodgkin lymphoma (HL), treatment with AVD+BV (doxorubicin, vinblastine, and dacarbazine+brentuximab vedotin) was not cost-effective vs conventional treatment with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).
Why this matters
- The most common first-line therapy for HL comprises ABVD; however, bleomycin has been associated with significant pulmonary toxicity.
- Markov model analysis to compare the cost-effectiveness of AVD+BV vs ABVD in the treatment of patients with newly diagnosed HL.
- Funding: Lowe Endowment Fund; National Heart, Lung, and Blood Institute; National Center for Advancing Translational Science.
- AVD+BV delivered an improvement of 0.56 quality-adjusted life years (QALYs) vs ABVD: 19.86 with AVD+BV vs 19.30 with ABVD.
- Treatment with AVD+BV was associated with a $361,137 lifetime healthcare cost vs $184,291 with ABvd.
- $317,254 per QALY incremental cost-effectiveness ratio for ABD + BV vs ABVD.
- Analysis was undertaken in the absence of long-term data for ABD +BV.